Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome.
APS
Antiphospholipid antibodies
Antiphospholipid syndrome
Autoimmunity
Extra-criteria
Primary APS
Thrombocytopenia
Thrombosis
aPL
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
19
02
2018
revised:
29
03
2018
accepted:
06
04
2018
pubmed:
12
5
2018
medline:
24
4
2019
entrez:
12
5
2018
Statut:
ppublish
Résumé
To investigate the long-term effect of B-cell depletion therapy with Rituximab (RTX) alone as rescue therapy in primary antiphospholipid syndrome (PAPS) patients with severe thrombocytopenia. We retrospectively retrieved data from patients who met the following inclusion criteria: (a) persistent antiphospholipid antibodies (aPL) positivity and fulfilled the Sydney criteria for PAPS (b) presented with severe thrombocytopenia (platelets <50,000/mm This retrospective study included 6 consecutive female PAPS patients [median age 49.5 (range 38-66)] who presented with severe thrombocytopenia (platelets <50,000/mm In one of the longest-term observational (median 43 months) studies, sustained clinical remission of severe thrombocytopenia without immunosuppressive maintenance therapy was obtained by RTX alone in patients with PAPS and severe thrombocytopenia intolerant or refractory to conventional therapy.
Identifiants
pubmed: 29747993
pii: S0049-0172(18)30097-0
doi: 10.1016/j.semarthrit.2018.04.001
pii:
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Immunosuppressive Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-744Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.